
AUG 2 1 2003



510(k) Summary of Safety and Effectiveness

Date: July 21, 2003

Submitter: GE Medical Systems Information Technologies

4502 Woodland Corporate Boulevard

Tampa, FL 33614 USA

Contact Person: Melissa Robinson

Regulatory Affairs Specialist

GE Medical Systems Information Technologies

Phone: 813-887-2133 Fax: 813-887-2545

<u>Device:</u> <u>Trade Name:</u> Corometrics Model 120 Maternal/Fetal Monitor

Common/Usual Name: Maternal/Fetal Monitor

Classification Names: 21 CFR 884.2740 System, Monitoring, Perinatal

<u>Predicate Devices:</u> K991739 Corometrics Model 120 Maternal/Fetal Monitor

K992238 Masimo SET® Radical Pulse Oximeter and LNOP® series of

sensors and cables

<u>Device Description:</u> The 120 Maternal/Fetal Monitoring System consists of the following

features/options that can be available in multiple configurations:

fetal heart rate (via Doppler Ultrasound of FECG)

maternal uterine activity (via intrauterine pressure catheter or tocotransducer

fetal movement detection

maternal non-invasive blood pressure (clinician prompted or

automatic)

maternal pulse oximetry

maternal heart/pulse rate (MECG) and ECG waveform "snapshot"

Intended Use: The 120 Maternal/Fetal Monitoring System is intended for monitoring

fetal and maternal vital signs: fetal heart rate; optional fetal movement detection, FHR and UA alarms; maternal uterine activity; heart/pulse

rate, blood pressure and %SpO₂.

Technology: The Corometrics Model 120 Maternal/Fetal Monitor employs the same

fundamental scientific technology as the predicate devices.

Test Summary: The Model 120 Maternal/Fetal Monitor complies with the voluntary

standards as detailed in Section 9 of this submission. The following quality assurance measures were applied to the development of the

Model 120:

Requirements specification review

Code inspections

Software and hardware testing

Safety testing

Environmental testing

Final validation

Conclusion: The results of these measurements demonstrated that the Model 120

Maternal/Fetal Monitor (with Masimo SET Pulse Oximetry) is as safe,

as effective, and performs as well as the predicate device.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 21 2003

Ms. Melissa Robinson Regulatory Affairs Specialist GE Medical Systems Information Technologies 4502 Woodland Corporate Blvd. TAMPA FL 33614 Re: K032252

Trade/Device Name: Corometrics Model 120

Maternal/Fetal Monitor

Regulation Number: 21 CFR 884.2740

Regulation Name: Perinatal monitoring system

with accessories

Regulatory Class: II Product Code: 85 HGM Dated: July 21, 2003 Received: July 22, 2003

Dear Ms. Robinson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Mancy C Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

510(k) Number (if known): 632252

Device Name:

Corometrics Model 120 Maternal/Fetal Monitoring System

Indications For Use:

I. Fetal Surveillance

A Corometrics 120 Maternal/Fetal Monitoring System is used for non-invasive and invasive monitoring of the fetus during the antepartum period as well as throughout labor and delivery (i.e. fetal heart rate and uterine activity monitoring). Fetal movement detection and fetal heart rate alarm options (user selectable high/low and poor signal quality alarms) are available.

II Maternal Monitoring

A Corometrics 120 Maternal/Fetal Monitoring System is intended for monitoring maternal vital signs to help assess maternal well-being. The vital signs which can be measured with these monitor configurations are summarized as follows:

NOTE: Maternal vital signs provided by the monitor should only be used as an adjunct in patient assessment in conjunction with clinical signs and symptoms.

Blood Pressure: The monitor is intended for use in the non-invasive monitoring of maternal blood pressure (NBP). This monitor is not intended for use in the neonatal or pediatric blood pressure monitoring.

Pulse Oximetry. The monitor is intended for use in the non-invasive monitoring of maternal functional oxygen saturation of arterial hemoglobin (MSpO2).

Heart/Pulse Rate. The monitor is intended for use in the non-invasive monitoring of the maternal heart/pulse rate. Additionally, an MECG waveform "snapshot" may be displayed and printed.

NOTE: Only the maximum configuration provides both maternal heart rate and pulse rate data.

Concurrence of CDRH, Offi	ce of Dev	rice Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)	OR	Over-The-Counter Use
(Division Sign-Off) Division of Reproductive, Abdominal,		(Optional Format 1-2-96)

24